IDH1 and astrocytoma (excluding glioblastoma): What we do know, however, is that the outcomes of this WHO grade 2/3 IDH-WT cohort with surgery and radiation are similar to the glioblastoma group and worse than IDH-mutant astrocytomas, irrespective of WHO grade.